The three projects of this grant are highly focused on evaluating the PTEN/MMAC1 tumor suppressor gene and the phosphoinositide 3-kinase (PI3K) signaling pathway in prostate cancer. PI3K has been implicated in prostate cancer because of the recent discovery that PTEN encodes a phosphatase that hydrolyzes the lipid products of cancers have defects in PTEN. Prostate cancer cell lines that lack PTEN have constitutive activation of enzymes down-stream of PI3K, including the AKT protein- Ser/Thr kinase and reintroduction of PTEN (or addition of PI3K inhibitors) blocks this pathway and leads to decreased cell growth and increased apoptosis. Although studies with cell lines suggest that inhibition of PI3K should block growth and survival of tumors that result from loss of PTEN, there is no evidence that this is true in vivo. Heterozygous loss of PTEN in mice results in hyperplasia in multiple tissues, including prostate and adenocarcinomas of the prostate. These mice provide a model for human prostate cancers that result from loss of PTEN. The goal of the proposed work is to test the effect of deleting genes of enzymes in the PI3K pathway on the development of prostate cancer in mice, and to develop techniques that will evaluate whether the PI3K pathway is activated in human prostate cancers. The proposed work involves extensive collaborations between the three projects and the three cores, taking advantage of the expertise of individual laboratories. In Project 1, the Cantley laboratory will generate mice in which the regulatory subunits of PI3K are deleted in the prostate. These mice will then be crossed with the mice that lack PTEN in order to determine whether loss of the PI3k regulatory subunit blocks the development of prostate cancers that result from loss of PTEN. In Project 2, the Robert's laboratory will generate mice in which the catalytic subunit of PI3K is deleted in the prostate for the sample purpose. Multiple genes for both the regulatory and catalytic subunits of PI3K is deleted in the prostate for the same purpose. Multiple genes for both the regulatory and catalytic subunit of PI3K is deleted in the prostate for the same purpose. Multiple genes for both the regulatory and catalytic subunits of PI3K exist in mice and men and these studies will indicate which of these is the most critical for prostate cancer development. In Project 3, the Sellers laboratory will evaluate additional proteins downstream of PI3K. For downstream targets judged to be critical for PI3K-dependent growth or survival of prostate cancer cell lines, prostate-specific expression of dominant- negative forms or targeted deletion of the genes will be performed. Pharmaceutical companies are currently developing PI3K catalytic site inhibitors, AKT inhibitors and inhibitors of the function of the regulatory subunit of PI3K. However, to date, the inhibitors available are not sufficiently specific and have problems with bioavailability and toxicity that preclude evaluation. These studies will suggest which of these proteins should be targeted for treatment of prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA089021-02
Application #
6514800
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mohla, Suresh
Project Start
2001-05-01
Project End
2006-03-31
Budget Start
2002-04-01
Budget End
2003-03-31
Support Year
2
Fiscal Year
2002
Total Cost
$1,853,371
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02215
Patnaik, Akash; Swanson, Kenneth D; Csizmadia, Eva et al. (2017) Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. Cancer Discov 7:750-765
Lee, So Jin; Kim, Min Ju; Kwon, Ick Chan et al. (2016) Delivery strategies and potential targets for siRNA in major cancer types. Adv Drug Deliv Rev 104:2-15
Martin, Neil E; Gerke, Travis; Sinnott, Jennifer A et al. (2015) Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. Mol Cancer Res 13:1431-40
Selvarajah, Shamini; Pyne, Saumyadipta; Chen, Eleanor et al. (2014) High-resolution array CGH and gene expression profiling of alveolar soft part sarcoma. Clin Cancer Res 20:1521-30
González-Billalabeitia, Enrique; Seitzer, Nina; Song, Su Jung et al. (2014) Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. Cancer Discov 4:896-904
Flavin, Richard; Pettersson, Andreas; Hendrickson, Whitney K et al. (2014) SPINK1 protein expression and prostate cancer progression. Clin Cancer Res 20:4904-11
Ittmann, Michael; Huang, Jiaoti; Radaelli, Enrico et al. (2013) Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res 73:2718-36
Chen, Sen; Jiang, Xinnong; Gewinner, Christina A et al. (2013) Tyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinases. Sci Signal 6:ra40
Jia, Shidong; Gao, Xueliang; Lee, Sang Hyun et al. (2013) Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov 3:44-51
Polkinghorn, William R; Parker, Joel S; Lee, Man X et al. (2013) Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov 3:1245-53

Showing the most recent 10 out of 94 publications